Phibro Animal Health (PAHC) Projected to Post Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) is projected to post its Q3 2025 quarterly earnings results after the market closes on Wednesday, May 7th. Analysts expect Phibro Animal Health to post earnings of $0.53 per share and revenue of $352.41 million for the quarter. Phibro Animal Health has set its FY 2025 guidance at 1.870-2.010 EPS.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.14. Phibro Animal Health had a net margin of 1.75% and a return on equity of 25.35%. On average, analysts expect Phibro Animal Health to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Phibro Animal Health Stock Performance

NASDAQ:PAHC traded up $0.88 during trading hours on Friday, reaching $19.48. 208,384 shares of the stock were exchanged, compared to its average volume of 189,190. The company has a quick ratio of 1.37, a current ratio of 3.20 and a debt-to-equity ratio of 2.99. Phibro Animal Health has a 52 week low of $16.06 and a 52 week high of $26.55. The firm has a 50 day simple moving average of $20.26 and a 200-day simple moving average of $21.98. The stock has a market capitalization of $789.00 million, a P/E ratio of 40.58, a P/E/G ratio of 0.45 and a beta of 0.62.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 26th. Shareholders of record on Wednesday, March 5th were issued a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, March 5th. This represents a $0.48 dividend on an annualized basis and a yield of 2.46%. Phibro Animal Health's dividend payout ratio is currently 100.00%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PAHC. Morgan Stanley set a $20.00 target price on shares of Phibro Animal Health in a research note on Tuesday, April 15th. StockNews.com downgraded Phibro Animal Health from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Finally, Barclays boosted their price target on shares of Phibro Animal Health from $20.00 to $22.00 and gave the stock an "underweight" rating in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company's stock. According to data from MarketBeat, Phibro Animal Health has a consensus rating of "Hold" and an average price target of $19.75.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.